A Clinical Pharmacology Study to Determine the Pharmacokinetic, Safety and Tolerability Profile of Oral Doses of AZD7295 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 13 Feb 2010
At a glance
- Drugs AZD 7295 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Arrow Therapeutics
- 13 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 30 May 2009 New trial record